Olcegepant
Olcegepant (INN,[1] code name BIBN-4096BS) is a calcitonin gene-related peptide receptor antagonist being studied as a potential treatment for migraines.[2]
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C38H47Br2N9O5 |
Molar mass | 869.645 g/mol g·mol−1 |
3D model (JSmol) | |
SMILES
| |
InChI
|
A 2013 meta-analysis found olcegepant and telcagepant were effective and safe compared to placebo.[3]
See also
References
- "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 48" (PDF). World Health Organization. pp. 256–7. Retrieved 20 March 2017.
- Tfelt-Hansen, P; Olesen, J (Apr 2011). "Possible site of action of CGRP antagonists in migraine". Cephalalgia : An International Journal of Headache. 31 (6): 748–50. doi:10.1177/0333102411398403. PMID 21383046.
- Yao, Gang; Yu, Tingmin; Han, Ximei; Mao, Xijing; Li, Bo (2013-04-05). "Therapeutic effects and safety of olcegepant and telcagepant for migraine: A meta-analysis". Neural Regeneration Research. 8 (10): 938–947. doi:10.3969/j.issn.1673-5374.2013.10.009. ISSN 1673-5374. PMC 4145922. PMID 25206386.
This article is issued from
Wikipedia.
The text is licensed under Creative
Commons - Attribution - Sharealike.
Additional terms may apply for the media files.